Allogene Therapeutics ALLO
NASDAQ ALLO
$0.90 -0.03 (-3.41%)
At close: Nov 11, 2026 · 4:00 PM EST

Allogene Therapeutics (ALLO) Total Debt (2018)

Updated

Allogene Therapeutics' Total Debt came in at $139.62 million for Q3 2018.

Analysis

Allogene Therapeutics (ALLO) Total Debt (2018) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Total Debt (Qtr)
1 Eli Lilly 1,348.13 Bn 1,321.74 Bn 20.46 Bn 49.50 Bn
2 Johnson & Johnson 675.90 Bn 595.76 Bn 17.30 Bn 44.65 Bn
3 AbbVie 519.45 Bn 487.50 Bn 13.12 Bn 80.90 Bn
4 Merck 364.95 Bn 327.95 Bn 13.19 Bn 53.78 Bn
5 Novartis Ag 311.58 Bn 285.16 Bn - -
6 Astrazeneca 289.34 Bn 262.94 Bn 13.26 Bn -6.68 Bn
7 Amgen 251.64 Bn 203.30 Bn 7.58 Bn 54.01 Bn
8 Gilead Sciences 212.05 Bn 187.07 Bn 6.73 Bn 26.23 Bn
9 Pfizer 167.35 Bn 115.00 Bn 12.56 Bn 62.67 Bn
10 Allogene Therapeutics 322.04 Mn -820.62 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2018 139.62 Mn
API Access

Allogene Therapeutics Total Debt API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=total-debt&ticker=ALLO&period=max&api_key=YOUR_API_KEY